docetaxel anhydrous has been researched along with bicalutamide in 40 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (bicalutamide) | Trials (bicalutamide) | Recent Studies (post-2010) (bicalutamide) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 1,313 | 212 | 541 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | bicalutamide (IC50) |
|---|---|---|---|
| Progesterone receptor | Oryctolagus cuniculus (rabbit) | 5.6 | |
| Progesterone receptor | Homo sapiens (human) | 1.819 | |
| Androgen receptor | Homo sapiens (human) | 0.404 | |
| Androgen receptor | Rattus norvegicus (Norway rat) | 0.7168 | |
| Androgen receptor | Mus musculus (house mouse) | 1.835 | |
| Testosterone 17-beta-dehydrogenase 3 | Homo sapiens (human) | 0.12 | |
| Progesterone receptor | Rattus norvegicus (Norway rat) | 0.89 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (20.00) | 29.6817 |
| 2010's | 25 (62.50) | 24.3611 |
| 2020's | 7 (17.50) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bassetto, M; Brancale, A; Ferla, S; Khandil, S; McGuigan, C; Pertusati, F; Westwell, AD | 1 |
| Amin, P; Chen, T; Dawson, N; Engstrom, C; Hussain, A; Naslund, M | 1 |
| Kibel, AS | 1 |
| Bhat-Nakshatri, P; Cheng, L; DeGrado, T; Gokmen-Polar, Y; Hutchins, GD; Jayaprakasan, V; Kelich, S; Miller, KD; Miller, MA; Nakshatri, H; Shanmugam, R; Sledge, GW; Sweeney, CJ; Yip-Schneider, M; Zheng, QH | 1 |
| Slovin, SF | 1 |
| Burich, RA; Holland, WS; Mack, PC; Tepper, C; Vinall, RL; White, RW | 1 |
| Bagalà, C; Barone, C; Bianchetti, S; Cassano, A; Fabiano, A; Landriscina, M; Piscazzi, A; Quirino, M; Schinzari, G; Sica, G | 1 |
| Holzapfel, K; Krause, BJ; Müller, SA; Seidl, C; Senekowitsch-Schmidtke, R; Treiber, U | 1 |
| Akdas, AM; Burch, PA; Crawford, ED; Dipaola, RS; Donnelly, BJ; Goldman, B; Higano, CS; Hussain, M; Petrylak, DP; Small, EJ; Sundram, SK; Tangen, C; Wilding, G | 1 |
| Agus, DB; Gross, ME; Jiang, Y; Palma, JF; Wang, Y | 1 |
| Habuchi, T; Horikawa, Y; Inoue, T; Kumazawa, T; Maita, S; Nanjyo, H; Narita, S; Numakura, K; Obara, T; Saito, M; Satoh, S; Tsuchiya, N; Tsuruta, H | 1 |
| Fujii, Y; Ishioka, J; Kawakami, S; Kihara, K; Kijima, T; Koga, F; Masuda, H; Matsuoka, Y; Numao, N; Saito, K; Yokoyama, M | 1 |
| Garnick, MB | 1 |
| Cristino, L; De Petrocellis, L; Di Marzo, V; Iappelli, M; Ligresti, A; Orlando, P; Schiano Moriello, A; Stott, CG; Verde, R | 1 |
| Bennett, HL; Fleming, JT; Leung, HY; Mandal, R; O'Prey, J; Robson, CN; Ryan, KM; Stockley, J | 1 |
| Date, S; Hirayama, K; Mukaisho, K; Nagashima, T; Niiro, M; Okihara, K | 1 |
| Browne, G; Lian, JB; McKeown, SR; Ming, L; Nesbitt, H; Stein, GS; Worthington, J | 1 |
| Bubley, G; Buckle, G; Ernstoff, MS; Kantoff, PW; Morganstern, DE; Nakabayashi, M; Taplin, ME; Walsh, W; Xie, W | 1 |
| Neal, DE; Zecchini, V | 1 |
| Antonarakis, ES; McMahan, ZH; Nadal, R | 1 |
| Gan, W; He, DL; Ji, HH; Jia, HT; Li, L; Li, YF; Xie, S; Zhang, SF; Zhang, TT | 1 |
| Chaudhary, U; Golshayan, AR; Keane, TE; Kraft, AS; Marshall, DT; Ramey, S | 1 |
| Daverede, L; Harnden, P; Jagdev, SP; Paul, A; Ralph, C; Trainor, S; Trigonis, I; Vasudev, NS; Weston, M | 1 |
| Duensing, S; Grüllich, C; Hadaschik, BA; Höfner, T; Hohenfellner, M; Jäger, D; Pahernik, S; Vallet, S | 1 |
| Armstrong, C; Gao, AC; Liu, C; Lou, W; Sandher, A; Zhu, Y | 1 |
| Carballido, EM; Dow, EN; Horsley-Silva, JL; Lindor, KD; Menias, CO; Smith, ML; Vargas, HE | 1 |
| Badiozamani, KR; Beyer, DC; Harris, J; Horwitz, EM; Hurwitz, MD; Lawton, CAF; Michalski, JM; Roof, K; Sandler, HM; Sartor, O; Shayegan, B; Sperduto, PW; Xiao, Y; Zhang, Q | 1 |
| Lei, BH; Lu, ZJ; Wang, Y; Zhang, Y; Zhu, QY; Zou, Q | 1 |
| Bohr, A; Grohganz, H; Harmankaya, N; Löbmann, K; Nascimento, TL; Rades, T; Wang, Y; Weisser, JJ | 1 |
| Abraham, C; Banu, E; Beuzeboc, P; Bozec, L; Caty, A; Culine, S; Delva, R; Deplanque, G; Elaidi, R; Ferrero, JM; Gomez, P; Gravis, G; Hardy-Bessard, AC; Houede, N; Krakowski, I; Lagrange, JL; Latorzeff, I; Linassier, C; Miglianico, L; Mouret, L; Muracciole, X; Oudard, S; Priou, F; Ravaud, A; Rolland, F; Sevin, E; Voog, E; Zylberait, D | 1 |
| Adomat, H; Beraldi, E; Bidnur, S; Bowden, M; Fazil, L; Gleave, ME; Jackson, JK; Kesch, C; Moskalev, I; Schmitt, V; Thi, M; Yago, V | 1 |
| Beraldi, E; Bidnur, S; Bowden, M; Gleave, ME; Jackson, JK; Kesch, C; Schmitt, V; Yago, V | 1 |
| Abdelhamid, MI; Abdelrahman, AE; Alnagar, AA; Elwan, A; Nawar, N | 1 |
| Carpenter, V; Faber, AC; Gewirtz, DA; Harada, H; Min Lee, S; Murray, G; Reed, J; Saleh, T; Souers, A | 1 |
| Guo, Z; Hu, X; Liu, Z; Lv, R; Meng, L; Yan, L; Zhang, Y | 1 |
| Abe, H; Amiya, Y; Hayashi, S; Kaneko, Y; Kimura, N; Nakatsu, H; Shima, T; Suzuki, N; Takei, A; Tetsuka, T; Uchida, T | 1 |
| Aaltomaa, S; Ahlgren, G; Andrén, O; Brasso, K; Castellanos, E; Damber, JE; de Wit, R; Holmberg, E; Jellvert, Å; Josefsson, A; Luukkaa, M; Meidahl Petersen, P; Seke, M; Verhagen, P; Widmark, A | 1 |
2 review(s) available for docetaxel anhydrous and bicalutamide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
An interdisciplinary approach to treating prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Nitriles; Prednisone; Prostatectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Tosyl Compounds | 2005 |
8 trial(s) available for docetaxel anhydrous and bicalutamide
| Article | Year |
|---|---|
Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: preliminary results.
Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Finasteride; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Paclitaxel; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Salvage Therapy; Taxoids; Tosyl Compounds | 2001 |
Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Docetaxel; Estramustine; Goserelin; Humans; Male; Middle Aged; Mitoxantrone; Nitriles; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Tosyl Compounds | 2009 |
Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Therapy, Combination; Estramustine; Follow-Up Studies; Goserelin; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Prostatic Neoplasms; Retrospective Studies; Taxoids; Time Factors; Tosyl Compounds; Treatment Outcome | 2013 |
Intermittent tri-weekly docetaxel plus bicalutamide in patients with castration-resistant prostate cancer: a single-arm prospective study using a historical control for comparison.
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Docetaxel; Drug Administration Schedule; Humans; Male; Middle Aged; Nitriles; Orchiectomy; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids; Tosyl Compounds | 2013 |
Phase I trial of weekly docetaxel, total androgen blockade, and image-guided intensity-modulated radiotherapy for localized high-risk prostate adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Docetaxel; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nitriles; Prostatic Neoplasms; Radiotherapy, Image-Guided; Radiotherapy, Intensity-Modulated; Taxoids; Tosyl Compounds; Treatment Outcome | 2014 |
[Clinical efficacy of integrated traditional Chinese and Western medicine for castration-resistant prostate cancer].
Topics: Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Goserelin; Humans; Male; Nitriles; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Tosyl Compounds; Treatment Outcome | 2017 |
Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Risk; Tosyl Compounds; Triptorelin Pamoate | 2019 |
Effect of docetaxel added to bicalutamide in Hormone-Naïve non-metastatic prostate cancer with rising PSA, a randomized clinical trial (SPCG-14).
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Disease-Free Survival; Docetaxel; Hormones; Humans; Male; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome | 2023 |
30 other study(ies) available for docetaxel anhydrous and bicalutamide
| Article | Year |
|---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
Topics: Anilides; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; CHO Cells; Cricetulus; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Ether-A-Go-Go Potassium Channels; Humans; Hydrocarbons, Fluorinated; Male; Mice; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Structure-Activity Relationship; Sulfhydryl Compounds; Tosyl Compounds | 2019 |
Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model.
Topics: Androgen Antagonists; Anilides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Cell Line, Tumor; Docetaxel; Drug Synergism; Endothelium, Vascular; Fibroblast Growth Factor 2; Humans; JNK Mitogen-Activated Protein Kinases; Male; Mice; Mice, Nude; Neovascularization, Pathologic; NF-kappa B; Nitriles; Prostatic Neoplasms; Radionuclide Imaging; Sesquiterpenes; Taxoids; TNF Receptor-Associated Factor 1; TNF Receptor-Associated Factor 2; Tosyl Compounds; Umbilical Veins; Vascular Endothelial Growth Factor A | 2006 |
Does small-cell phenotype predict the natural history of prostate cancer? A case study in disease behavior.
Topics: Adenocarcinoma; Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Docetaxel; Estramustine; Etoposide; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Nephrostomy, Percutaneous; Nitriles; Phenotype; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Tosyl Compounds; Transurethral Resection of Prostate; Urinary Diversion | 2007 |
Genistein combined polysaccharide enhances activity of docetaxel, bicalutamide and Src kinase inhibition in androgen-dependent and independent prostate cancer cell lines.
Topics: Androgens; Anilides; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Docetaxel; Drug Synergism; Genistein; Humans; Male; Neoplasms, Hormone-Dependent; Nitriles; Prostatic Neoplasms; Pyrimidines; src-Family Kinases; Taxoids; Tosyl Compounds | 2008 |
Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Animals; Cell Differentiation; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Dihydrotestosterone; Docetaxel; Drug Synergism; Humans; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Nevirapine; Nitriles; Prostatic Neoplasms; Random Allocation; Receptors, Androgen; Reverse Transcriptase Inhibitors; RNA, Neoplasm; Signal Transduction; Taxoids; Tosyl Compounds; Xenograft Model Antitumor Assays | 2009 |
Characterization of choline uptake in prostate cancer cells following bicalutamide and docetaxel treatment.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Biological Transport; Cell Line, Tumor; Choline; Diffusion; Docetaxel; Hemicholinium 3; Humans; Male; Nitriles; Organic Cation Transport Proteins; Positron-Emission Tomography; Prostatic Neoplasms; Radiopharmaceuticals; Taxoids; Tosyl Compounds; Tritium | 2009 |
Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Castration; Docetaxel; Humans; Male; Mutation; Neoplastic Cells, Circulating; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Taxoids; Tosyl Compounds | 2010 |
Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized p
Topics: Aged; Androgens; Anilides; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Estramustine; Female; Follow-Up Studies; Humans; Leuprolide; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Survival Rate; Taxoids; Tosyl Compounds; Treatment Outcome | 2012 |
Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Estrogens; Humans; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids; Tosyl Compounds | 2012 |
Editorial comment. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estrogens; Humans; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Tosyl Compounds | 2012 |
Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms.
Topics: Androgen Antagonists; Anilides; Animals; Apoptosis; Cannabidiol; Cannabinoids; Caspase 3; Cell Cycle; Cell Survival; Docetaxel; Down-Regulation; Dronabinol; Drug Interactions; Humans; Male; Mice; Mice, Nude; Nitriles; Prostate; Prostatic Neoplasms; Reactive Oxygen Species; Receptors, Androgen; Taxoids; Tosyl Compounds; Transient Receptor Potential Channels; TRPM Cation Channels; Tumor Cells, Cultured | 2013 |
Does androgen-ablation therapy (AAT) associated autophagy have a pro-survival effect in LNCaP human prostate cancer cells?
Topics: Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Blotting, Western; Cell Line, Tumor; Cell Survival; Docetaxel; Flow Cytometry; Humans; Immunohistochemistry; Male; Microscopy, Confocal; Nitriles; Prostatic Neoplasms; RNA, Small Interfering; Sensitivity and Specificity; Taxoids; Tosyl Compounds | 2013 |
[Prostate carcinoma with squamous differentiation after combination endocrine therapy: a case report].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Fluorouracil; Goserelin; Humans; Lymph Node Excision; Male; Nitriles; Prostatectomy; Prostatic Neoplasms; Taxoids; Tosyl Compounds | 2012 |
Bicalutamide-induced hypoxia potentiates RUNX2-mediated Bcl-2 expression resulting in apoptosis resistance.
Topics: Anilides; Animals; Antineoplastic Agents; Apoptosis; Cell Hypoxia; Cell Survival; Core Binding Factor Alpha 1 Subunit; Docetaxel; Humans; Male; Mice; Mice, SCID; Nitriles; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids; Tosyl Compounds; Tumor Cells, Cultured; Up-Regulation; Xenograft Model Antitumor Assays | 2012 |
Targeting the pro-survival side-effects of androgen-deprivation therapy in prostate cancer.
Topics: Anilides; Autophagy; Cell Line, Tumor; Docetaxel; Humans; Male; Nitriles; Taxoids; Tosyl Compounds | 2013 |
Paraneoplastic palmar fasciitis and polyarthritis syndrome in a patient with advanced prostate cancer.
Topics: Adrenal Cortex Hormones; Androgen Antagonists; Anilides; Antineoplastic Agents; Arthritis; Docetaxel; Fasciitis; Humans; Male; Middle Aged; Nitriles; Paraneoplastic Syndromes; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Tosyl Compounds | 2013 |
Metastatic castrate-resistant prostate cancer with a late, complete and durable response to docetaxel chemotherapy: a case report.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Docetaxel; Goserelin; Humans; Lymphatic Metastasis; Male; Nitriles; Prostate; Prostatic Neoplasms; Taxoids; Tosyl Compounds; Treatment Failure; Treatment Outcome | 2014 |
Docetaxel followed by abiraterone in metastatic castration-resistant prostate cancer: efficacy and predictive parameters in a large single center cohort.
Topics: Aged; Androgen Antagonists; Androstenes; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Buserelin; Cohort Studies; Disease-Free Survival; Docetaxel; Flutamide; Humans; Leuprolide; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Nitriles; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Tosyl Compounds; Treatment Outcome; Triptorelin Pamoate | 2015 |
Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer.
Topics: Adenosine Triphosphatases; Adenosine Triphosphate; Androgen Antagonists; Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Benzamides; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Rhodamines; Taxoids; Tosyl Compounds; Xenograft Model Antitumor Assays | 2015 |
Docetaxel Induced Sclerosing Cholangitis.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Amiodarone; Anilides; Anti-Arrhythmia Agents; Antineoplastic Agents; Carbazoles; Carvedilol; Cholangitis, Sclerosing; Docetaxel; Dronedarone; Drug Interactions; Humans; Leuprolide; Male; Nitriles; Propanolamines; Taxoids; Tosyl Compounds | 2015 |
Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621.
Topics: Adenocarcinoma; Adult; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Kallikreins; Male; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Staging; Nitriles; Proportional Hazards Models; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Taxoids; Tosyl Compounds | 2017 |
Efflux Inhibitor Bicalutamide Increases Oral Bioavailability of the Poorly Soluble Efflux Substrate Docetaxel in Co-Amorphous Anti-Cancer Combination Therapy.
Topics: Administration, Oral; Anilides; Animals; Biological Availability; Docetaxel; Drug Stability; Drug Synergism; Humans; Nitriles; Rats; Solubility; Tosyl Compounds; X-Ray Diffraction | 2019 |
A polymeric paste-drug formulation for intratumoral treatment of prostate cancer.
Topics: Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Docetaxel; Drug Compounding; Humans; Male; Mice; Nitriles; Polymers; Prostatic Neoplasms; Rats; Tissue Distribution; Tosyl Compounds; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Design and Characterization of Injectable Poly(Lactic-Co-Glycolic Acid) Pastes for Sustained and Local Drug Release.
Topics: Anilides; Animals; Antineoplastic Agents; Docetaxel; Drug Carriers; Drug Compounding; Drug Liberation; Drug Stability; Humans; Injections; Lidocaine; Male; Mice; Mice, Nude; Neoplasms, Experimental; Nitriles; Ointments; Polylactic Acid-Polyglycolic Acid Copolymer; Prostatic Neoplasms; Rats; Tosyl Compounds; Viscosity | 2020 |
Clinicopathological Features and Treatment Challenges in Triple Negative Breast Cancer Patients: A Retrospective Cohort Study.
Topics: Administration, Metronomic; Adult; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Capecitabine; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Nitriles; Retrospective Studies; Risk Factors; Time Factors; Tosyl Compounds; Triple Negative Breast Neoplasms; Young Adult | 2021 |
Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy.
Topics: Anilides; Aniline Compounds; Animals; Antineoplastic Agents; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Survival; Cellular Senescence; Docetaxel; Humans; Male; Mice; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Sulfonamides; Tosyl Compounds; Xenograft Model Antitumor Assays | 2021 |
Effect of Bicalutamide Combined with Docetaxel on Serum PSA and VEGF Levels in Patients with Advanced Prostate Carcinoma.
Topics: Anilides; Carcinoma; Docetaxel; Humans; Male; Nitriles; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Retrospective Studies; Tosyl Compounds; Vascular Endothelial Growth Factor A | 2022 |
Upfront Androgen Receptor-Axis-Targeted Therapies in Men with De Novo High-Volume Metastatic Hormone-Sensitive Prostate Cancer.
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies | 2023 |